Dr. Brose on Lenvatinib in Differentiated Thyroid Cancer
October 22nd 2015
Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses survival benefit and possible combination strategies with the lenvatinib in patients with radioactive iodine refractory differentiated thyroid cancer.